Skip to main content

Table 1 Basic characteristics of the participants

From: The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study

Characteristics

Non-fibrate user

Fibrate user

t/x 2

p

Subjects (N)

41

48

N/A

N/A

Age (yrs)

58.80 ± 12.68

57.71 ± 12.90

0.396

0.693

Women (%)

46.4

37.7

0.646

0.421

Diabetes duration (yrs)

10.39 ± 6.91

7.16 ± 4.92

2.514

*0.014

AL of the right eye (mm)

23.32 ± 0.40

23.45 ± 0.52

1.304

0.195

AL of the left eye (mm)

23.44 ± .0.56

23.61 ± 0.64

1.322

0.189

IOP of the right eye (mmHg)

19.11 ± 3.32

18.47 ± 4.01

0.811

0.419

IOP of the left eye (mmHg)

18.77 ± 3.99

18.34 ± 4.17

0.494

0.622

BMI(kg/m2)

24.63 ± 2.62

25.74 ± 2.43

−2.044

*0.044

Laboratory findings

 HbA1c (%)

8.52 ± 0.29

8.46 ± 0.28

0.991

0.324

 Total cholesterol (mmol/l)

4.43 ± 0.21

4.75 ± 0.16

−8.148

*0.000

 Triglyceride (mmol/l)

2.20 ± 0.28

3.02 ± 0.21

−15.76

*0.000

 LDL (mmol/l)

2.74 ± 0.14

2.81 ± 0.12

−1.817

0.072

 HDL (mmol/l)

1.27 ± 0.04

1.21 ± 0.05

6.177

*0.000

 ACR (μg/mg creatinine)

23.15 ± 35.72

27.49 ± 44.64

−0.500

0.618

DR status (%)

 No DR

34.1

35.5

2.335

0.311

 Mild NPDR

48.7

57.7

 Moderate NPDR

17

6.6

Diabetes treatment (%)

 Sulfonylurea

62.5

58.3

0.035

0.852

 Insulin

12.5

16.6

0.065

0.798

  1. Each participant who used fenofibrate was exactly matched with a non-fibrates user for gender, age and DR status. BMI body mass index, DR diabetic retinopathy, HbA1c glycated hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, RNFL retinal nerve fiber layer, AL axial length, and IOP intraocular pressure. Data represented the mean ± standard deviation (SD) of each group. * p < 0.05. p < 0.05 was considered statistically significant. Diabetes duration, BMI, total cholesterol, triglyceride, HDL were found significant difference between groups